• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA warns of flesh-eating genital infection linked to diabetes drug

August 31, 2018 By Fink Densford

FDA

The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes.

The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin that surrounds muscles, nerves, fat and blood vessels of the perineum, were reported by users of the drug.

The FDA said that a single patient was reported to have died from the infection, and that all patients were hospitalized and required surgery, with some requiring “multiple disfiguring surgeries.”

The drugs are produced by Johnson & Johnson‘s (NYSE:JNJ) Ivokana, Eli Lilly‘s (NYSE:LLY) Jardiance, Bristol-Myers Squibb (NYSE:BMY), Astra Zeneca (NYSE:AZN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE), according to a Reuters report, which said that the producing companies had not yet responded to a request for comment.

The FDA said that SGLT2 inhibitors are approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes, and that the inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine.

The agency said that any patients experiencing symptoms of tenderness, redness or swelling of the genitals or area from the genitals to the back of the rectum on the drug seek medical attention immediately.

The federal watchdog said that it is requiring a new warning be added to labels of the drug.

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly & Co., johnsonandjohnson, Merck, Pfizer Inc.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Reader Interactions

Comments

  1. MARIE says

    November 15, 2018 at 11:42 am

    YOU THINK THE ANSWER IS TO PUT A WARNING ON THE BOTTLE OF THE MEDICINE WITH NECROTIZING FASCIITIS. WARNING. LET ME TELL YOU GET OUT THERE SEE WHAT THIS DOES TO PEOPLE. MY FRIEND GOT YOUR NECROTIZING FASCIITIS IN JUNE 2018 AFTER 21 SURGERIES, SKIN GRAFTING, TWO MONTHS IN REHAB WHERE SHE STILL IS AS WE SPEAK WOULD DISAGREE WITH YOUR WARNING. THATS JUST SO YOU CAN SAY IF YOU GET IT WELL IT WAS ON THE WARNING LABEL. YOU NEED TO PULL THIS STUFF OFF THE SHELF. IF YOU THINK A WARNING IS ENOUGH THEN A CLASS ON THE ILLNESS SHOULD BE MANDATORY SO THAT THEY REALLY UNDERSTAND YOUR WARNING. I HAVE SEEN MY FRIEND ALMOST DIE TWICE, HAVE PAIN THAT NO PERSON SHOULD EXPERIENCE, I SAW HOLES IN HER BODY WHERE SHE WAS JUST EATEN AWAY. PLEASE YOU NEED TO DO MORE THAN JUST A WARNING. YOU ALSO NEED TO INVOLVE METFORMIN IN YOUR LIST ITS NOT A INHIBITOR BUT IS INVOLVED IN HALF THE ONES YOU MENTION.

    • S says

      April 26, 2019 at 7:28 am

      Makes too much $… just like other products they are mandating now. They are hushed.

    • Rita Gregoire says

      August 19, 2019 at 5:23 am

      I totally agree!!! My husband is going through this right now!! He has been in the hospital since July 9th and their saying at LEAST two more months!!! He has lost more then have of the mussel tissue in his leg… four operations and now they have been using a ” wound vacuum ” for the last three weeks before they can start the grafting because the wound is so big!!

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS